Penumbra, Inc. (NYSE:PEN) Shares Bought by Sei Investments Co.

Sei Investments Co. raised its stake in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 18.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 107,616 shares of the company's stock after purchasing an additional 17,027 shares during the period. Sei Investments Co. owned 0.28% of Penumbra worth $25,557,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PEN. FMR LLC lifted its holdings in shares of Penumbra by 2.1% in the third quarter. FMR LLC now owns 5,896,396 shares of the company's stock worth $1,145,729,000 after buying an additional 121,465 shares in the last quarter. State Street Corp lifted its position in Penumbra by 0.3% during the third quarter. State Street Corp now owns 1,236,671 shares of the company's stock valued at $240,298,000 after purchasing an additional 3,863 shares during the last quarter. RTW Investments LP grew its position in Penumbra by 7.2% in the third quarter. RTW Investments LP now owns 795,750 shares of the company's stock worth $154,622,000 after acquiring an additional 53,645 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in shares of Penumbra by 23.4% in the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company's stock worth $173,416,000 after purchasing an additional 138,387 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in Penumbra by 128.1% during the third quarter. Janus Henderson Group PLC now owns 668,873 shares of the company's stock worth $129,967,000 after buying an additional 375,684 shares during the period. Hedge funds and other institutional investors own 88.88% of the company's stock.

Remove Ads

Penumbra Stock Down 0.9 %

NYSE:PEN traded down $2.47 during mid-day trading on Friday, hitting $267.16. 304,864 shares of the company's stock traded hands, compared to its average volume of 404,370. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The company has a market capitalization of $10.29 billion, a P/E ratio of 785.75, a P/E/G ratio of 2.83 and a beta of 0.51. The company has a fifty day moving average of $274.55 and a 200 day moving average of $243.18. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.09. The firm had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. On average, analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Buying and Selling at Penumbra

In other news, Director Harpreet Grewal sold 167 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the transaction, the director now directly owns 8,530 shares of the company's stock, valued at approximately $2,058,118.40. This represents a 1.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arani Bose sold 12,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total transaction of $3,405,240.00. Following the transaction, the director now directly owns 314,819 shares of the company's stock, valued at $89,336,187.63. This represents a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,518 shares of company stock worth $26,400,219. 5.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

PEN has been the subject of several recent analyst reports. Royal Bank of Canada boosted their target price on Penumbra from $285.00 to $313.00 and gave the company an "outperform" rating in a research report on Wednesday, February 19th. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a report on Wednesday, February 19th. Oppenheimer initiated coverage on shares of Penumbra in a research report on Tuesday, December 17th. They set an "outperform" rating and a $275.00 target price on the stock. StockNews.com cut shares of Penumbra from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Morgan Stanley lifted their price objective on shares of Penumbra from $240.00 to $260.00 and gave the company an "equal weight" rating in a report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $294.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.